|
RFFL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.44679998274E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.12239999960906E-07 |
| Normal-vs-Stage2 |
8.161100E-03 |
| Normal-vs-Stage3 |
1.84339999931282E-08 |
| Normal-vs-Stage4 |
2.28369989585531E-10 |
| Stage1-vs-Stage2 |
5.227600E-01 |
| Stage1-vs-Stage3 |
4.002400E-02 |
| Stage1-vs-Stage4 |
2.769600E-04 |
| Stage2-vs-Stage3 |
9.945600E-02 |
| Stage2-vs-Stage4 |
1.370070E-02 |
| Stage3-vs-Stage4 |
1.270420E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.58060042621378E-10 |
| Normal-vs-AfricanAmerican |
3.943000E-01 |
| Normal-vs-Asian |
2.42539999972813E-07 |
| Caucasian-vs-AfricanAmerican |
2.719800E-01 |
| Caucasian-vs-Asian |
4.666800E-01 |
| AfricanAmerican-vs-Asian |
1.940390E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.79049999954928E-07 |
| Normal-vs-Female |
1.06959999746081E-08 |
| Male-vs-Female |
9.184400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.93419999805889E-08 |
| Normal-vs-Age(41-60Yrs) |
3.20460000002853E-06 |
| Normal-vs-Age(61-80Yrs) |
1.18559999595647E-08 |
| Normal-vs-Age(81-100Yrs) |
1.063760E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.984800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.359600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.974200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.374980E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.253600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.608400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.19609999682524E-08 |
| Classical-VS-Follicular |
2.213600E-01 |
| Classical-VS-Other |
9.347200E-01 |
| Classical-VS-Normal |
1.23339999991146E-07 |
| Tall-VS-Follicular |
9.43379999673866E-08 |
| Tall-VS-Other |
6.515800E-02 |
| Tall-VS-Normal |
8.25117751901416E-13 |
| Follicular-VS-Other |
6.362200E-01 |
| Follicular-VS-Normal |
4.774000E-04 |
| Other-VS-Normal |
3.846500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.05279999998531E-07 |
| Normal-vs-N1 |
1.8733000000104E-06 |
| N0-vs-N1 |
1.685760E-01 |
|
|
